MSY3 Inhibitors
MSY3 inhibitors are a class of chemical compounds that specifically target the MSY3 protein, a member of the Y-box binding protein family. This protein, also known as YBX3 or CSDA, is a transcription factor and RNA-binding protein, playing a crucial role in regulating gene expression at both transcriptional and post-transcriptional levels. MSY3 contains a conserved cold-shock domain, which is essential for its ability to bind DNA and RNA. By inhibiting MSY3 activity, these compounds can influence a range of cellular processes, particularly those associated with mRNA stability, translation, and cellular stress responses. MSY3 inhibitors typically interact with this protein either by direct binding to its active sites or by disrupting its interactions with nucleic acids, leading to modulation of the gene regulatory networks in which MSY3 is involved.
The mechanism of MSY3 inhibitors often centers around the disruption of RNA binding and regulatory functions. MSY3 is known to participate in the assembly of stress granules and influences the fate of mRNA molecules under various conditions, such as oxidative stress and nutrient deprivation. Inhibiting this protein can impact mRNA decay, translation efficiency, and the overall dynamics of protein synthesis. Additionally, since MSY3 is involved in chromatin remodeling and the regulation of non-coding RNAs, inhibitors may also affect epigenetic processes and the expression of long non-coding RNAs (lncRNAs). The detailed structural interactions between MSY3 inhibitors and the protein often involve hydrophobic and hydrogen bond interactions, which can be tailored to specific regions of the cold-shock domain to enhance selectivity and potency. These molecular interactions form the basis of ongoing research into the precise roles of MSY3 in cellular regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin is an inhibitor of non-muscle myosin II ATPase activity. By inhibiting this enzyme, blebbistatin impedes myosin II's ability to contribute to cytoskeletal reorganization, a process that MSY3 can be involved in during cell movement. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is a specific inhibitor of myosin light chain kinase (MLCK). Inhibition of MLCK results in decreased phosphorylation of myosin light chains, which could attenuate MSY3-related functions in cytoskeletal dynamics and muscle contraction. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase). ROCK is part of a pathway that regulates actin cytoskeleton dynamics and myosin-driven contractility, which are cellular functions potentially involving MSY3 activity. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö 6976 is an inhibitor of calcium/calmodulin-dependent protein kinase (CaMK). By inhibiting CaMK, Gö 6976 could disrupt calcium signaling pathways that regulate muscle contraction and other processes where MSY3 may play a role. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a selective inhibitor of CaMKII, which is involved in calcium signaling pathways. By inhibiting CaMKII, KN-93 may indirectly inhibit MSY3 function related to muscle contraction and other calcium-dependent cellular processes. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 is an inhibitor of calmodulin, which is a calcium-binding messenger protein. By inhibiting calmodulin, W-7 can disrupt calcium-mediated processes, including those that could involve MSY3's function in muscle cell contraction and signaling. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum inhibitor of matrix metalloproteinases (MMPs). While its primary action is on MMPs, it could potentially alter the extracellular environment affecting MSY3's role in cell adhesion and migration. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD 98059 could inhibit MSY3 function in pathways related to muscle differentiation and cell motility that involve MAPK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAP kinase. The p38 pathway is involved in stress responses and cytoskeletal changes, and inhibition of this kinase could inhibit MSY3-related signaling in cellular responses to stress and muscle function. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a selective inhibitor of BMP type I receptors ALK2 and ALK3. By inhibiting these receptors, LDN-193189 could indirectly inhibit MSY3 function in bone morphogenetic protein (BMP) signaling pathways related to muscle formation. | ||||||